Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VGX Pharmaceuticals Inc.

Division of Inovio Pharmaceuticals Inc.
www.vgxp.com

Latest From VGX Pharmaceuticals Inc.

Inovio Links With GeneOne For MERS Immunotherapy

Amid the recent climb in the number of confirmed cases of lethal Middle East Respiratory Syndrome (MERS) in South Korea, Inovio Pharmaceuticals and GeneOne Life Science have said they will advance Inovio's DNA vaccine for MERS into a clinical trial in healthy volunteers.

BioPharmaceutical South Korea

Inovio, GeneOne Get DARPA Grant For Ebola Biologics

A consortium including South Korea-based GeneOne Life Sciences will receive a grant of up to $56 million from the U.S. Defense Advanced Research Projects Agency (DARPA) for the development of multiple treatment and prevention approaches against Ebola.

BioPharmaceutical South Korea

Roche Adds To Its Immuno-Oncology Investments With Inovio Licensing Deal

Swiss pharma licenses rights to a pair of preclinical, multi-antigen DNA immunotherapies for prostate cancer and hepatitis B, as well as delivery technology. Inovio gets $10 million up front and can earn milestones up to $412.5 million.

BioPharmaceutical United States

Inovio promotes Niranjan Sardesai to COO

Inovio Pharmaceuticals, which is developing vaccines to fight cancers and infectious diseases, has promoted Dr Niranjan Sardesai from senior vice-president of research and development to chief operating officer. In addition, Kevin Rassas, Inovio's senior vice-president of business development, has retired. Dr Sardesai will incorporate corporate and business development responsibilities into his expanded role. Dr Sardesai joined VGX Pharmaceuticals in 2006, before the company merged with Inovio in June 2009.

See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Viral Genomix Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Inovio Pharmaceuticals Inc.
  • Senior Management
  • J. Joseph Kim, PhD, Pres. & CEO
    Gene J Kim, CFO
    Kevin W Rassas, SVP, Bus. Dev.
  • Contact Info
  • VGX Pharmaceuticals Inc.
    Phone: (267) 440-4200
    450 Sentry Pkwy.
    Blue Bell, PA 19422
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register